Published online Jan 28, 2015. doi: 10.3748/wjg.v21.i4.1216
Peer-review started: June 28, 2014
First decision: August 6, 2014
Revised: August 20, 2014
Accepted: September 29, 2014
Article in press: September 30, 2014
Published online: January 28, 2015
Processing time: 214 Days and 4.7 Hours
AIM: To investigate the correlation among tumor markers, curative resection, and recurrence in gastric cancer.
METHODS: The patients with preoperative tumor makers [Carcinoembryonic antigen, Carbohydrate antigen (CA) 19-9, and CA 125] and elective gastrectomy between January 2000 and December 2009 at Chungbuk National University Hospital were enrolled in this study. We analyzed the relationship among the tumor makers, curative resection and recurrence, retrospectively.
RESULTS: Among the 679 patients with gastric cancer, curative resection was 93.6% (n = 636) and non-curative resection was 6.4% (n = 43). The independent risk factors for the non-curative resection were tumor location and the positivity of preoperative serum CA 19-9 and CA 125 levels. After curative resection, the independent prognostic risk factors for recurrence in curative resection were gender, stage, and preoperative increased serum CA 125 level (HR = 2.431, P =0.020), in a multivariate analysis.
CONCLUSION: Preoperative CA 125 is a useful predictive biomarker for curative resection and prognostic biomarker for recurrence in gastric cancer patients.
Core tip: Tumor marker such as carcinoembryonic antigen, Carbohydrate antigen (CA) 19-9, and CA 125 in gastric cancer are usual tools for predicting prognosis or monitoring. The aim of this study was to investigate the correlation among tumor markers, curative resection, and recurrence in gastric cancer. Our data showed that preoperative CA 19-9 and CA 125 are independent risk factor of non-curative operation. And preoperative CA 125 is independent risk factor for recurrence after curative operation. Preoperative CA 125 is considered useful marker for predicting curative operation and prediction of recurrence after curative resection in gastric cancer patients.